Several molecular alterations associated with SS have been identified and used as potential targets for therapy, including SS18‐SSX,11 IGF‐1R,12 BCL2,13 TLE114 and Wnt/β catenin pathway components (LEF1, TCF7, ZIC2, WNT5A, AXIN2 and FZD10).12 This evidence concerns the gene SS18 and synovial sarcoma.